- Definition

Represents the amount of additional payments to be made by the entity upon the achievement of certain development and commercialization milestones under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementAdditionalPaymentsToBeMadeUponAchievementOfCertainDevelopmentAndCommercializationMilestones
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the further license fee payable upon the achievement of certain clinical and regulatory milestones under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementFurtherLicenseFee
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the initial license fee under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementInitialLicenseFee
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Milestone Payments

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementMilestonePayments
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the nonrefundable payments made by the entity under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementNonrefundablePaymentMade
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the period for payment of royalties after the date of the first commercial sale in such country of any product including the licensed compound.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementPeriodAfterDateOfFirstCommercialSaleOfProductForPaymentOfRoyalties
Namespace Prefix:	rdus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty as a percentage of net sales of any product by the Company or its sublicenses under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementRoyaltyRate
Namespace Prefix:	rdus_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	rdus_CollaborativeArrangementsTypeOfAgreementAxis=rdus_EisaiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_TypeOfAgreementAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_CollaborativeArrangementsTypeOfAgreementAxis=rdus_SCRASSASAndAffiliatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreements (Details) € in Millions	1 Months Ended			2 Months Ended		6 Months Ended		7 Months Ended	10 Months Ended	142 Months Ended
License Agreements (Details) € in Millions	Mar. 31, 2015 USD ($)	Sep. 30, 2005 USD ($)	Sep. 30, 2005 EUR (€)	Jun. 30, 2017 USD ($)	Jun. 30, 2017 EUR (€)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Dec. 31, 2006 USD ($)	Dec. 31, 2015 USD ($)	Jun. 30, 2017 USD ($)
License Agreements
Milestone payments that triggered intangible asset recognition						$ 8,712,000	$ 0
Eisai \| License Agreement
License Agreements
Period after the date of the first commercial sale of the product for license expiration	10 years
Initial license fee paid								$ 500,000	$ 400,000
Eisai \| License Agreement \| Maximum
License Agreements
Payments to be made upon achievement of certain clinical and regulatory milestones	$ 22,300,000.0
Collaborative Arrangement \| Ipsen
License Agreements
Nonrefundable, non-creditable payment										$ 13,000,000
Milestone payments that triggered intangible asset recognition				$ 8,700,000	€ 8.0
Royalty rate (as a percent)		5.00%	5.00%
Collaborative Arrangement \| Ipsen \| Minimum
License Agreements
Period after the date of the first commercial sale of the product for license expiration		10 years	10 years
Collaborative Arrangement \| Ipsen \| Maximum
License Agreements
Additional payments to be made upon achievement of certain development and commercialization milestones		$ 27,400,000	€ 24.0